Long Pharmaron/Short Wuxi: Take Profit Now, A-Share Pullback the Key Risk
Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...
648 Views
2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance
Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...
723 Views
Pharmaron Beijing: Trading Debut, Valuation Scenario Analysis
Pharmaron Beijing Co Ltd-H (3759 HK) is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
590 Views
Hong Kong Buyback Weekly: Yichang HEC, Viva Biotech, China Literature Led the Buybacks
In the past 7 days, the top 3 companies that repurchased the most shares from the market were Yichang Hec Changjiang Pharmaceutical Co., Ltd. (1558...
409 Views
Pharmaron Beijing IPO: H-Share Valuation Enticing
Pharmaron Beijing Co Ltd-H (3759 HK)Â is a global contract research organisation (CRO) and is one of the top three drug discovery service providers...
762 Views